Analysis of Correlation between Body Mass Index and the Incidence of Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation

Document Type : Original Article

Authors

1 Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Hematology, Faculty Member of Islamic Azad University, Chalus Branch, Iran

10.22062/jkmu.2021.91762

Abstract

Background: Graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Identifiying the probable risk factors can help the clinicians manage the consequences of GVHD. The main aim of this study was to analyze the correlation of body mass index (BMI) as a risk factor with the GVHD incidence.
Methods: This retrospective study was conducted on 199 patients who received allo-HSCT during 2007-2017, as well as their donors. Almost all included patients received 10/10 human leukocyte antigen )HLA(-matched allogeneic stem cell transplants. The clinical data, including BMI, underlying disease and GVHD incidence, were collected from the clinical records.
Results: In the present study, GVHD was seen in 77 (38.6%) patients, including 59 acute and 18 chronic GVHD. The most frequent BMI range in both donors (35.5%) and recipients (45.2%) was between 18.5- 24.9 kg/m2. The transplants in which the BMI of donors were below 18.5 kg/m2 had 58% lower odds of GVHD incidence, compared to those with obese donors (CI: [0.21-0.85]; P = 0.05). Conversely, the donors with a BMI between 18.5 and 24.9 kg/m2 led to a 19% higher odds of GVHD incidence, especially acute GVHD, than transplants from donors with BMI above 30 kg/m2 (CI: [0.68-2.09]; P = 0.09). The recipients with a BMI between 18.5 and 24.9 kg/m2 had the odds of GVHD incidence 63% more than those with a BMI above 30 kg/m2 (CI: [0.89-3.06]; P= 0.3).
Conclusions: The findings of the present study suggest the donor's BMI as a probable GVHD risk factor so that the BMI lower than 18.5 kg/m2 was statistically correlated with a decreased incidence of GVHD.

Keywords


  1. Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 2017; 377(22):2167-9. doi: 10.1056/NEJMra1609337.
  2. Zeiser R, Socié G, Blazar BR. Pathogenesis of acute graft - versus - host disease: from intestinal microbiota alterations to donor T cell activation. Br J Haematol 2016; 175(2):191-207. doi: 10.1111/bjh.14295.
  3. Cutler CS, Koreth J, Ritz J. Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood 2017; 129(1):22-9. doi: 10.1182/blood-2016-08-686659.
  4. Ardakani MT, Mehrpooya M, Mehdizadeh M, Beiraghi N, Hajifathali A, Kazemi MH. Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplant 2019; 55(4):830-2. doi: 10.1038/s41409-019-0623-0.
  5. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12(6):443-58. doi: 10.1038/nri3212.
  6. Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 2017; 377(26):2565-79. doi: 10.1056/NEJMra1703472.
  7. Lee SJ, Nguyen TD, Onstad L, Bar M, Krakow EF, Salit RB, et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2018; 24(3):555-62. doi: 10.1016/j.bbmt.2017.10.042.
  8. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12(3):252-66. doi: 10.1016/j.bbmt.2006.01.008.
  9. Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12(4):375-96. doi: 10.1016/j.bbmt.2006.02.003.
  10. Fuji S, Kim SW, Yoshimura K, Akiyama H, Okamoto SI, Sao H, et al. Possible association between obesity and posttransplantation complications including infectious diseases and acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15(1):73-82. doi: 10.1016/j.bbmt.2008.10.029.
  11. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11(2):183-90. doi: 10.1038/nm1166.
  12. Conde J, Scotece M, Gomez R, López V, Gómezā€Reino JJ, Lago F, et al. Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. Biofactors 2011; 37(6):413-20. doi: 10.1002/biof.185.
  13. Heinbokel T, Floerchinger B, Schmiderer A, Edtinger K, Liu G, Elkhal A, et al. Obesity and its impact on transplantation and alloimmunity. Transplantation 2013; 96(1):10-6. doi: 10.1097/TP.0b013e3182869d2f.
  14. Deeg HJ, Seidel K, Bruemmer B, Pepe MS, Appelbaum FR. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 1995; 15(3):461-8.
  15. Navarro WH, Agovi MA, Logan BR, Ballen K, Bolwell BJ, Frangoul H, et al. Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant 2010; 16(10):1442-50. doi: 10.1016/j.bbmt.2010.04.009.
  16. Yang J, Xue SL, Zhang X, Zhou YN, Qin LQ, Shen YP, et al. Effect of body mass index on overall survival of patients with allogeneic hematopoietic stem cell transplantation. Eur J Clin Nutr 2017; 71(6):750-4. doi: 10.1038/ejcn.2016.225.
  17. Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 2005; 293(2):203-11. doi: 10.1001/jama.293.2.203.
  18. Gaudet M, Fara AG, Beritognolo I, Sabatti M. Allele-specific PCR in SNP genotyping. Methods Mol Biol 2009; 578:415-24. doi: 10.1007/978-1-60327-411-1_26.
  19. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21(3):389-401. doi: 10.1016/j.bbmt.2014.12.001.
  20. Fuji S, Takano K, Mori T, Eto T, Taniguchi S, Ohashi K, et al. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. Bone Marrow Transplant 2014; 49(12):1505-12. doi: 10.1038/bmt.2014.178.
  21. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373(9674):1550-61. doi: 10.1016/S0140-6736(09)60237-3.
  22. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007; 3(12):716-24. doi: 10.1038/ncprheum0674.
  23. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology 2006; 6(10):772-83.
  24. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4(5):371-9. doi: 10.1038/nri1350.
  25. Hasenkrug KJ. The leptin connection: regulatory T cells and autoimmunity. Immunity 2007; 26(2):143-5. doi: 10.1016/j.immuni.2007.02.002.
  26. De Rosa V, Procaccini C, Cali G, Pirozzi G, Fontana S, Zappacosta S, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007; 26(2):241-55. doi: 10.1016/j.immuni.2007.01.011.
  27. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112(12):1796-808. doi: 10.1172/JCI19246.
  28. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, et al. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation 2018; 53(7):932-7. doi: 10.1038/s41409-018-0100-1.
  29. Hadjibabaie M, Tabeefar H, Alimoghaddam K, Iravani M, Eslami K, Honarmand H, et al. The relationship between body mass index and outcomes in leukemic patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Transplant 2012; 26(1):149-55. doi: 10.1111/j.1399-0012.2011.01445.x.